GEN Exclusives

More »

Feature Articles

More »
Sep 15, 2011 (Vol. 31, No. 16)

New Products Launched at ELA

  • Go For the Gold

    IBIS Technologies showed off its IBIS MX96 surface plasmon resonance (SPR) system for label-free imaging of biomolecular interactions. The instrument is designed to work in conjunction with the company’s Continuous Flow Microspotter (CFM), which uses a network of microchannels to print arrays on the surface of sensors from dilute 70 µL ligand samples, said Richard Schasfoort, Ph.D., CSO.

    Sensor chips with standard or custom dimensions are available from the company, with surfaces ranging from bare gold to a variety of capture surfaces and activation chemistries. Typical applications range from kinetic rate and affinity constant measurements of antigen-antibody pairs, to antibody selectivity testing and even identification of individual epitopes involved in antibody binding.

    The latest system developments allow for a higher throughput and at least 20-fold greater sensitivity than IBIS’ earlier platforms, said Dr. Schasfoort. By exploiting its multiplexing capabilities, for example, 10,000 sensorgrams can be obtained overnight, which affords significant productivity increases.

    This multiplexing can be used to measure a given interaction using multiple different ligand densities and analyte concentrations in a single experiment, and the software can calculate highly accurate affinity constants in a way that avoids inaccuracies typically imposed by ligand re-binding effects as encountered with conventional platforms. For customers who choose not to purchase their own system, IBIS also provides its services as a CRO.

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Easing Restrictions for Terminal Patients

Should the Federal Government Pass a “Right to Try” Bill Allowing Terminally Ill Patients Access to Experimental Medicines?

More »